Kadcyla 100mg

Kadcyla 100mg is a prescription anti-cancer medicine containing trastuzumab emtansine, an antibody-drug conjugate used to treat certain types of HER2-positive breast cancer. It combines trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), with DM1, a cytotoxic agent that interferes with cell division.

HER2 is a protein present on the surface of certain cells that helps regulate cell growth. Some breast cancers produce excessive amounts of this protein, encouraging cancer cells to grow and multiply. Kadcyla binds to HER2 on cancer cells and delivers DM1 into these cells, helping disrupt their division and promote cell death.

Kadcyla is used for specific cases of HER2-positive breast cancer, including certain patients with early breast cancer who have residual invasive disease after neoadjuvant treatment and those with HER2-positive unresectable locally advanced or metastatic breast cancer who have received previous treatment. Eligibility depends on the approved indication and the patient’s clinical circumstances.

How Does Kadcyla 100mg Work?

Kadcyla 100mg is a targeted anticancer medicine administered through intravenous infusion. It belongs to a class of medicines known as antibody-drug conjugates, which combine a targeted antibody with a cell-killing agent.

The trastuzumab component attaches to HER2 proteins on cancer cells. Following binding and internalization into the cells, Kadcyla releases the DM1 component, which inhibits microtubule function. Microtubules are essential for cell division, and disrupting their function can prevent cancer cells from multiplying and lead to cell death.

The trastuzumab component also helps interfere with HER2-related signaling and may support immune-mediated destruction of cancer cells. This targeted mechanism helps direct the cytotoxic agent towards HER2-expressing cells, although healthy tissues may also be affected.

Kadcyla is not suitable for every type of breast cancer. Treatment requires confirmation of HER2-positive disease and an assessment of previous therapies, cancer stage, liver function, cardiac health and overall treatment suitability by an oncologist.

Dosage of Kadcyla 100mg :

Kadcyla 100mg is a prescription medicine supplied as a powder for preparing an intravenous infusion. It must be reconstituted and administered by qualified healthcare professionals in a suitable clinical setting. It is not intended for oral use or self-administration.

For most approved indications, the usual recommended dose is 3.6 mg per kilogram of body weight, administered intravenously every three weeks (21-day cycle). The exact treatment schedule and duration depend on whether Kadcyla is being used for early-stage or advanced breast cancer and the patient’s response and tolerance.

For early HER2-positive breast cancer with residual invasive disease after neoadjuvant treatment, Kadcyla is generally administered for 14 cycles unless recurrence or unacceptable toxicity occurs. For unresectable locally advanced or metastatic HER2-positive breast cancer, treatment generally continues until disease progression or unacceptable toxicity.

The 100mg vial represents the quantity of medicine supplied, not necessarily the complete dose required for an individual patient. The oncologist determines the dose according to body weight, treatment indication and clinical condition. Dose reductions or treatment interruptions may be necessary if serious side effects develop.

Regular monitoring of liver function, platelet counts and cardiac function is essential during treatment. Kadcyla must only be used under specialist supervision.

Benefits of Using Kadcyla 100mg :

Kadcyla 100mg is a targeted treatment for eligible patients with HER2-positive breast cancer. Its antibody-drug conjugate formulation combines HER2-directed therapy with a cytotoxic agent to help control cancer growth.

Targeted treatment: The trastuzumab component binds to HER2 proteins on cancer cells, helping deliver DM1 to these cells.

Inhibits cell division: DM1 disrupts microtubule function, interfering with the process cancer cells need to divide and multiply.

Treatment for early breast cancer: Kadcyla may be prescribed to eligible patients with residual invasive HER2-positive breast cancer following neoadjuvant treatment and surgery.

Treatment for advanced breast cancer: It is an established option for certain patients with HER2-positive unresectable locally advanced or metastatic breast cancer who have received previous treatment.

Combines two therapeutic components: The antibody and cytotoxic agent work together through complementary mechanisms to target HER2-expressing cancer cells.

Supports an individualized treatment plan: The medicine can form part of a specialist-led treatment strategy based on cancer characteristics, previous therapy and the patient’s clinical condition.

Treatment benefits vary between individuals. Kadcyla does not guarantee a cure, and its suitability must be determined by an oncologist after reviewing HER2 test results and other relevant clinical findings.

Side Effects of Kadcyla 100mg :

Kadcyla may cause side effects ranging from mild symptoms to serious complications. Their severity depends on individual health, treatment response and other clinical factors. Commonly reported side effects include:

• Fatigue and weakness
• Nausea and vomiting
• Musculoskeletal pain
• Headache
• Constipation
• Low platelet counts
• Increased liver enzyme levels
• Bleeding or easy bruising
• Peripheral neuropathy, including tingling or numbness in the hands and feet

Kadcyla can also cause serious liver injury, cardiac dysfunction, lung inflammation and infusion-related reactions. In rare cases, it may cause severe liver complications or life-threatening respiratory problems. Contact a healthcare professional promptly if you experience unusual bleeding, yellowing of the skin or eyes, persistent cough, breathing difficulties or symptoms of heart failure, such as swelling or breathlessness.

Liver function, platelet counts and heart function should be assessed before and during treatment. Kadcyla can cause fetal harm, so pregnancy status and appropriate contraception must be discussed with the treating specialist. Breastfeeding recommendations should also be reviewed with the healthcare team.

This medicine must be administered under specialist supervision, with treatment adjustments made when clinically necessary.

Conclusion :

Kadcyla 100mg (trastuzumab emtansine) is a targeted anticancer medicine used to treat specific types of HER2-positive breast cancer. Its suitability, dosage and treatment duration depend on the approved indication, previous therapies and individual health factors. Specialist administration and regular monitoring are essential for safe treatment.

Important Medical Warning :

Use Kadcyla 100mg strictly according to your oncologist’s prescription. Follow all instructions regarding treatment, monitoring and follow-up appointments. Do not attempt to administer this medicine yourself or change or discontinue treatment without medical advice. Kadcyla must be prepared and administered by qualified healthcare professionals. Report any unusual symptoms or suspected side effects to your treating team promptly.